Sandostatin · DIN 00839205 · 100 mcg/mL · injection solution
General benefit; Health Canada lists this DIN as Cancelled post market since 2024-03-25 — choose a marketed DIN from the same-category list.Discontinued March 25, 2024 · checked November 17, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-03-25 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-03-25 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Sandostatin · DIN 00839205
Manufacturer: Novartis Pharma Canada Inc.; listing date 2007-01-02
Health Canada: Cancelled post market since 2024-03-25 · brand SANDOSTATIN · ATC H01CB02 OCTREOTIDE · form Solution · route Intravenous, Subcutaneous · ingredients OCTREOTIDE (OCTREOTIDE ACETATE) 100 MCG/ML · company Se-cure pharmaceuticals and cosmetics ltd · schedule Prescription
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00839205)
Source record
DIN 00839205: Sandostatin
Raw flags: sec3=Y
Item: 920000084; group id 942; item number 2243; lccId None; manufacturer id NOV
Source form: Inj Sol; strength: 100mcg/mL
Recorded listing: General benefit
Source prices (unrounded): $10.0880; ministry $5.0440
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00839205
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9916
Interchangeable products
Octreotide Acetate Omega · DIN 02248640 · $5.0440
Octreotide Injection · DIN 02560240 · $5.0440
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since March 25, 2024 — choose a marketed DIN from the same-category list.